Q3 2024 EPS Estimates for GSK plc Boosted by Zacks Research (NYSE:GSK)

GSK plc (NYSE:GSK) – Analysts at Zacks Research increased their Q3 2024 earnings estimates for shares of GSK in a note issued to investors on Wednesday, May 22nd. Zacks Research analyst E. Bagri now forecasts that the pharmaceutical company will post earnings of $1.25 per share for the quarter, up from their previous forecast of $1.18. The consensus estimate for GSK’s current full-year earnings is $4.10 per share. Zacks Research also issued estimates for GSK’s FY2024 earnings at $4.19 EPS, Q1 2025 earnings at $1.11 EPS, Q4 2025 earnings at $0.97 EPS, FY2025 earnings at $4.41 EPS, Q1 2026 earnings at $1.18 EPS and FY2026 earnings at $4.88 EPS.

GSK (NYSE:GSK) last released its earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.94 by $0.15. The company had revenue of $9.34 billion during the quarter, compared to the consensus estimate of $8.98 billion. GSK had a return on equity of 51.54% and a net margin of 14.62%.

Several other equities analysts have also weighed in on the stock. Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. Citigroup upgraded GSK from a “neutral” rating to a “buy” rating in a report on Tuesday, February 13th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, GSK presently has a consensus rating of “Moderate Buy”.

GSK Stock Performance

GSK stock opened at $45.17 on Thursday. The company has a market cap of $93.61 billion, a PE ratio of 16.37, a PEG ratio of 1.35 and a beta of 0.65. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.15. GSK has a 1 year low of $33.33 and a 1 year high of $45.92. The company’s 50-day moving average is $42.47 and its two-hundred day moving average is $40.06.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be given a dividend of $0.3762 per share. This represents a $1.50 dividend on an annualized basis and a dividend yield of 3.33%. This is a boost from GSK’s previous quarterly dividend of $0.36. The ex-dividend date of this dividend is Thursday, May 16th. GSK’s dividend payout ratio (DPR) is currently 53.26%.

Hedge Funds Weigh In On GSK

Institutional investors and hedge funds have recently made changes to their positions in the company. Versant Capital Management Inc grew its holdings in shares of GSK by 2,816.7% in the 4th quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock valued at $26,000 after buying an additional 676 shares during the period. Register Financial Advisors LLC acquired a new position in shares of GSK in the 1st quarter valued at $31,000. Larson Financial Group LLC grew its holdings in shares of GSK by 271.8% in the 3rd quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company’s stock valued at $32,000 after buying an additional 647 shares during the period. BKM Wealth Management LLC acquired a new position in shares of GSK in the 4th quarter valued at $32,000. Finally, Richardson Financial Services Inc. acquired a new position in shares of GSK in the 4th quarter valued at $40,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.